Close Menu

Lab901

Agilent Technologies has launched Genomic DNA ScreenTape, a prepackaged consumables device that works with the company’s 2200 TapeStation instrument to determine the quantity, size and quality of genomic DNA in less than two minutes per sample, using one microlit

Lab901's automated benchtop gel electrophoresis system and associated consumables are expected to complement Agilent's existing commercial offerings for gel electrophoresis. Lab901 also has a fledgling multiplex PCR-based diagnostic business that Agilent will review in coming weeks.

While Agilent said the purchase would "address customer needs across the entire span of electrophoresis life-science applications," Lab901 also provides applications for array users.

"With this technology and the team that developed it now part of Agilent, we can expand our reach in the pharmaceutical and clinical mass spec markets," an Agilent official said of the Biocius purchase.

Some microarray firms, such as Oxford Gene Technology, have adopted Lab901's ScreenTape for RNA quality control purposes.

John Anson, R&D director at OGT, said that the UK company adopted Lab901's system to improve the quality of its services business.

Lab901 will optimize its ScreenTape PCR diagnostics platform for use with Biofortuna’s multiplex PCR diagnostics kits for the detection of celiac disease and other HLA-related disease such as reactive arthritis, diabetes, and drug hypersensitivity.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.